What is Lifesci Capital’s Forecast for OVID Q2 Earnings?

Ovid Therapeutics (NASDAQ:OVID) – Investment analysts at Lifesci Capital decreased their Q2 2026 earnings per share estimates for shares of Ovid Therapeutics in a research note issued to investors on Wednesday, May 13th. Lifesci Capital analyst F. Brisebois now anticipates that the company will post earnings of ($0.10) per share for the quarter, down from their previous estimate of ($0.08). The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.49) per share. Lifesci Capital also issued estimates for Ovid Therapeutics’ Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.12) EPS and FY2026 earnings at ($0.45) EPS.

Several other research analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a report on Tuesday, April 21st. BTIG Research restated a “buy” rating and set a $4.00 target price on shares of Ovid Therapeutics in a report on Thursday, March 26th. Wedbush restated an “outperform” rating and set a $7.00 target price on shares of Ovid Therapeutics in a report on Wednesday, April 15th. Wall Street Zen upgraded Ovid Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Finally, HC Wainwright boosted their target price on Ovid Therapeutics from $2.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $5.13.

Ovid Therapeutics Price Performance

NASDAQ:OVID opened at $2.80 on Friday. The firm has a market cap of $369.26 million, a P/E ratio of -9.66 and a beta of 0.18. The stock has a 50 day moving average of $2.48 and a two-hundred day moving average of $1.88. Ovid Therapeutics has a 12 month low of $0.27 and a 12 month high of $3.11. The company has a current ratio of 10.17, a quick ratio of 8.97 and a debt-to-equity ratio of 0.06.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Ovid Therapeutics had a negative return on equity of 22.51% and a negative net margin of 240.11%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its holdings in Ovid Therapeutics by 497.7% in the fourth quarter. Goldman Sachs Group Inc. now owns 170,457 shares of the company’s stock valued at $278,000 after acquiring an additional 141,940 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in Ovid Therapeutics in the third quarter valued at approximately $264,000. Graham Capital Management L.P. acquired a new position in Ovid Therapeutics in the fourth quarter valued at approximately $208,000. Quadrature Capital Ltd lifted its holdings in Ovid Therapeutics by 217.2% in the fourth quarter. Quadrature Capital Ltd now owns 87,874 shares of the company’s stock valued at $143,000 after acquiring an additional 60,171 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new position in Ovid Therapeutics in the third quarter valued at approximately $69,000. 72.24% of the stock is currently owned by institutional investors and hedge funds.

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.